CHITOGENX INC. - Results demonstrate protection from knee joint degeneration and osteoarthritis development post meniscal repair surgery
- Results provide further evidence that the Company's proprietary chitosan-based biopolymer, combined with PRP can potentially bring significant benefit to human tissue repair
In a study of 22 mature sheep, a radial meniscus tear was surgically induced and immediately surgically repaired. The sheep were randomized to three groups: i) surgery alone, ii) surgery and PRP, and iii) surgery + ORTHO-R and PRP combined. Results were observed 6 months post-surgery.
Results showed that the large majority of menisci from the two control groups (surgery alone or surgery + PRP alone) experienced severe structural changes and most control sheep displayed moderate to severe signs of osteoarthritis ("OA"). The medial menisci from the ORTHO-R treated group retained better structure and much milder form of OA and, in some cases, appeared near normal.
This study provides the first evidence that treatment with
"We are very excited with the results of this large animal study. We expected our technology to demonstrate the same results as the rotator cuff repair study in 48 sheep reported on in 2022, namely that shoulder rotator cuff repair was found to be more structurally sound with respect to tendon tissue integrity than in a control group of surgery alone. In this study, we found similar results with respect to meniscus integrity, with the added benefit of being protective from developing knee osteoarthritis following meniscal repair surgery, while surgery alone, and surgery with PRP, alone were not," reported
This study contributes to a growing and strong body of evidence that the Company's proprietary chitosan-based biopolymer, combined with PRP can potentially bring significant benefit to human tissue repair.
As previously announced on
Other formulations are being developed to leverage the technology's performance characteristics such as tissue adhesion, pliability, and ability to deliver biologics or therapeutics to various tissues damaged by trauma or disease. Further information about ChitogenX is available on the Company's website at www.chitogenx.com and on SEDAR at www.sedar.com.
This news release may contain certain forward-looking statements regarding the Company's expectations for future events. Such expectations are based on certain assumptions that are founded on currently available information. If these assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. Factors that could cause actual results to differ include, amongst others, uncertainty as to the final result and other risks. The Company disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by security laws.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
SOURCE
© Canada Newswire, source
